Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
People with diabetes and chronic kidney disease (CKD) are at high risk for kidney failure, atherosclerotic cardiovascular disease, heart failure, and premature mortality. Recent clinical trials support new approaches to treat diabetes and CKD. The 2022 American Diabetes Association (ADA) Standards of Medical Care in Diabetes and the Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease each provide evidence-based recommendations for management. A joint group of ADA and KDIGO representatives reviewed and developed a series of consensus statements to guide clinical care from the ADA and KDIGO guidelines. The published guidelines are aligned in the areas of CKD screening and diagnosis, glycemia monitoring, lifestyle therapies, treatment goals, and pharmacologic management. Recommendations include comprehensive care in which pharmacotherapy that is proven to improve kidney and cardiovascular outcomes is layered on a foundation of healthy lifestyle. Consensus statements provide specific guidance on use of renin-angiotensin system inhibitors, metformin, sodium–glucose cotransporter-2 inhibitors, glucagon-like peptide 1 receptor agonists, and a nonsteroidal mineralocorticoid receptor antagonist. These areas of consensus provide clear direction for implementation of care to improve clinical outcomes of people with diabetes and CKD.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Kidney International |
| Vol/bind | 102 |
| Udgave nummer | 5 |
| Sider (fra-til) | 974-989 |
| Antal sider | 16 |
| ISSN | 0085-2538 |
| DOI | |
| Status | Udgivet - 2022 |
Bibliografisk note
Funding Information:
IHdB’s employer receives research support from Dexcom, and he has received honoraria from the ADA. He is a consultant to or advisory board member of AstraZeneca, Bayer, Boehringer Ingelheim, Cyclerion Therapeutics, George Clinical, Goldfinch Bio, and Ironwood Pharmaceuticals. He is also deputy editor for the Clinical Journal of the American Society of Nephrology. KK’s institution has received research grants from AstraZeneca, Boehringer Ingelheim, Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, and Sanofi, and he is a consultant to Abbott, Amgen, AstraZeneca, Bayer, Berlin-Chemie AG/Menarini Group, Boehringer Ingelheim, Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Roche, Sanofi, and Servier. TS’s employer receives research support from Transplant House, and she has received honoraria from AstraZeneca. KRT has received research grants from Bayer, Goldfinch Bio, and Travere Therapeutics. She is a consultant to or advisory board member of AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Gilead Sciences, Goldfinch Bio, Novo Nordisk, and Travere Therapeutics. JJN is an advisory board member for Novo Nordisk and Sanofi and is on Dexcom’s speakers bureau. CMR has received a research grant from Dexcom and honoraria from AstraZeneca. She has also received funding from Fresenius Medical Care and ReCor Medical. SER’s employer receives research grants from Bayer, and she is a consultant to or advisory board member of Bayer, Reata Pharmaceuticals, and Relypsa. She is the president-elect of the National Kidney Foundation. PR has received research support from Astellas Pharma, AstraZeneca, Bayer, Boehringer Ingelheim, Gilead Sciences, Merck Sharp & Dohme, Mundipharma, Novo Nordisk, Sanofi, and Vifor Pharma. GB is a consultant to or advisory board member of Alnylam Pharmaceuticals, AstraZeneca, Bayer, DiaMedica Therapuetics, Horizon Therapeutics, inRegen, Ionis Pharmaceuticals, KBP Biosciences, Merck, Novo Nordisk, and Quantum Genomics.
Publisher Copyright:
© 2022 World Kidney Day
ID: 325454163